Oregon Health & Science University
Oregon Health & Science University
Portland, Oregon, United States261 results · Page 1 of 11
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Double Blind Study Performed to Evaluate the Efficacy and the Safety of EscharEx in Debridement of VLU (VALUE) | Leg Ulcer, Skin Ulcer, Skin and Connective Tissue Diseases, Varicose Ulcer, cardiovascular disorder, skin disorder, varicose disease, vascular disorder | Recruiting | Phase 3 | 2026-10-09 | NCT06568627 | |
| EXtubation Related Complications - the EXTUBE Study (EXTUBE) | Extubation | Recruiting | Not stated | 2026-10-09 | NCT06442930 | |
| RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis | Neoplasms by Site, Paraneoplastic Syndromes, Nervous System, autoimmune disease, autoimmune disorder of the nervous system, immune system disorder, myasthenia gravis, neoplasm, nervous system disorder, neurodegenerative disease, neuromuscular disease, neuromuscular junction disease, paraneoplastic syndrome | Recruiting | Phase 1 / Phase 2 | 2026-10-09 | NCT06359041 | |
| A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Digestive System Diseases, Infant, Newborn, Diseases, cystic fibrosis, hereditary disease, lung disorder, pancreas disorder, respiratory system disorder | Active, not recruiting | Phase 3 | 2026-10-09 | NCT05444257 | |
| Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, brain disorder, breast disorder, breast neoplasm, central nervous system cancer, central nervous system disorder, neoplasm, nervous system disorder, skin disorder | Recruiting | Phase 1 / Phase 2 | 2026-10-09 | NCT05386108 | |
| A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Precursor Cell Lymphoblastic Leukemia-Lymphoma, acute biphenotypic leukemia, acute leukemia of ambiguous lineage, acute myeloid leukemia, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, mixed phenotype acute leukemia, myeloid leukemia, neoplasm | Recruiting | Phase 1 / Phase 2 | 2026-10-09 | NCT04065399 | |
| An Exploratory Study of the Potential for Rational Immune System Manipulation to Prevent Emergence of Synucleinopathy Manifestations in Persons With REM Sleep Behavior Disorder (RBD) | Nutritional and Metabolic Diseases, Parasomnias, REM Sleep Parasomnias, REM sleep behavior disorder, metabolic disease, nervous system disorder, neurodegenerative disease, proteostasis deficiencies, psychiatric disorder, sleep-wake disorder, synucleinopathy | Recruiting | Phase 2 | 2026-10-08 | NCT06996652 | |
| Impact of Fluciclovine (18F) PET (Positron Emission Tomography) on the Management of Prostate Cancer Following Negative or Equivocal PSMA (Prostate-Specific Membrane Antigen) PET Imaging at the Time of Biochemical Recurrence | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorder | Recruiting | Phase 4 | 2026-10-07 | NCT07569926 | |
| The HYALEX Pivotal Study | Damaged Chondral or Osteochondral Area | Recruiting | Not applicable | 2026-10-07 | NCT06368700 | |
| A Study to Evaluate the Safety and Efficacy of JZP926 Capsule for the Treatment of Juvenile Myoclonic Epilepsy | Epilepsies, Myoclonic, Epilepsy, Generalized, Epileptic Syndromes, brain disorder, central nervous system disorder, epilepsy, juvenile myoclonic epilepsy, nervous system disorder | Recruiting | Phase 2 / Phase 3 | 2026-10-06 | NCT07723963 | |
| Study to Evaluate the Safety and Efficacy of Larsucosterol in Participants With Alcohol-associated Hepatitis (AH) | Chemically-Induced Disorders, Digestive System Diseases, alcohol-induced disorders, alcohol-related disorders, alcoholic hepatitis, alcoholic liver disease, hepatitis, liver disorder, substance-related disorder | Recruiting | Phase 3 | 2026-10-06 | NCT07428538 | |
| A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease | Alzheimer disease, Cognition Disorders, Cognitive Dysfunction, brain disorder, central nervous system disorder, cognitive disorder, dementia, nervous system disorder, neurodegenerative disease, psychiatric disorder, tauopathy | Active, not recruiting | Phase 3 | 2026-10-06 | NCT03887455 | |
| A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension | Familial Primary Pulmonary Hypertension, Skin and Connective Tissue Diseases, cardiovascular disorder, connective tissue disorder, hypertensive disorder, lung disorder, pulmonary arterial hypertension, pulmonary hypertension, respiratory system disorder, vascular disorder | Enrolling by invitation | Phase 3 | 2026-10-06 | NCT03683186 | |
| Combining Ipilimumab With Abiraterone Acetate Plus Prednisone in Chemotherapy and Immunotherapy-naïve Patients With Progressive Metastatic Castration-resistant Prostate Cancer | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorder | Active, not recruiting | Phase 1 / Phase 2 | 2026-10-06 | NCT01688492 | |
| SARC041: Study of Abemaciclib Versus Placebo in Patients With Advanced Dedifferentiated Liposarcoma | Advanced Dedifferentiated Liposarcoma | Active, not recruiting | Phase 3 | 2026-10-05 | NCT04967521 | |
| A Study to Evaluate the Efficacy and Safety of Cannabidiol Oral Solution (CBD-OS [GWP42003-P, JZP926]) for the Treatment of Focal-Onset Seizures | Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Seizures, Focal, Signs and Symptoms, nervous system disorder, visual epilepsy | Recruiting | Phase 1 | 2026-10-02 | NCT07233239 | |
| CAR-T Long Term Follow Up (LTFU) Study | Long Term Safety of Patients Receiving CAR-T in an Eligible Clinical Trial or Managed Access Program | Recruiting | Phase 3 | 2026-10-02 | NCT02445222 | |
| Prevention of Ototoxicity in NTM Patients Treated With IV Amikacin | Chemically-Induced Disorders, Drug-Induced Ototoxicity, Drug-Related Side Effects and Adverse Reactions, Ear Diseases, Neurologic Manifestations, Ototoxicity, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Sensation Disorders, Signs and Symptoms, hearing disorder, hearing loss disorder, injury, nervous system disorder, otorhinolaryngologic disease, radiation injury | Recruiting | Phase 2 | 2026-10-01 | NCT05730283 | |
| A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Sezary syndrome, T-cell non-Hodgkin lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, mature T-cell and NK-cell non-Hodgkin lymphoma, mycosis fungoides, neoplasm, primary cutaneous T-cell non-Hodgkin lymphoma | Recruiting | Phase 1 | 2026-09-30 | NCT07192471 | |
| Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC | Locally Advanced Pancreatic Cancer | Active, not recruiting | Phase 3 | 2026-09-30 | NCT03257033 | |
| CoMind Early Feasibility Study | Brain Injuries, Traumatic, Craniocerebral Trauma, Encephalopathy, Hemorrhage, Intracranial Hemorrhages, Neuroinflammatory Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, brain disorder, brain injury, cardiovascular disorder, central nervous system disorder, cerebrovascular disorder, encephalitis, hydrocephalus, injury, intracerebral hemorrhage, nervous system disorder, nervous system injury, stroke disorder, vascular disorder | Recruiting | Not stated | 2026-09-29 | NCT06368648 | |
| First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors | Neoplasm Metastasis, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, neoplasm | Recruiting | Phase 1 / Phase 2 | 2026-09-29 | NCT05875168 | |
| Alzheimer's Disease Neuroimaging Initiative 4 | Alzheimer disease, Cognition Disorders, Cognitive Dysfunction, Frontotemporal Lobar Degeneration, Mild Cognitive Impairment, Pathological Conditions, Anatomical, Pathological Conditions, Signs and Symptoms, Pick disease, Plaque, Amyloid, brain disorder, central nervous system disorder, cognitive disorder, dementia, frontotemporal dementia, nervous system disorder, neurodegenerative disease, psychiatric disorder, tauopathy | Enrolling by invitation | Not stated | 2026-09-29 | NCT05617014 | |
| Study of ONO-4685 in Patients With Relapsed or Refractory T Cell Lymphoma | Disease Attributes, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, T-cell non-Hodgkin lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Active, not recruiting | Phase 1 | 2026-09-29 | NCT05079282 | |
| Modality Choice Before and After Failure for the Treatment of Painful Diabetic Neuropathy | Diabetes Complications, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Urogenital Diseases, diabetes mellitus, diabetic kidney disease, diabetic neuropathy, endocrine system disorder, kidney disorder, nervous system disorder, neuromuscular disease, peripheral nervous system disorder, urinary system disorder | Not yet recruiting | Phase 4 | 2026-09-28 | NCT07795593 |